Quantum Cyber N.V. (QUCY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.84 -7.69% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

Quantum Cyber N.V. (QUCY) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $79.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QUCY Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is QUCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Quantum Cyber N.V. (NASDAQ: QUCY) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.84 (-7.69% 1D, market cap $79.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QUCY ranks #685 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does QUCY compare to SDEV and INO in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QUCY carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 72.6%, and ROIC of -35.0%. By comparison, SDEV (Stablecoin Development Corporation) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $79.0M) and INO (Inovio Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $79.8M). Among the 5-stock peer group, QUCY leads on earnings multiple (N/A) while QUCY leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QUCY?
β–Ό

Per QUCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001874252), Quantum Cyber N.V. generated $537.1K in revenue (-39.9% YoY), -$16.2M in net income, and -$11.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.83 (-1.57%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (8)Whales (10)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$5 Bull$1 Base$1 Bear
πŸ“¬ FREE QUCY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for QUCY)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY QUCY SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+10/20 pts (29% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: Cash Engine Quality+8/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 39% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$1.03+3.9% Next Q
Q2 (-2Q)
40
Grade D$1.07-20.6% Next Q
Q3 (-1Q)
38
Grade E$0.85-1.2% Next Q
Current
35
Grade D-$0.84-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a QUCY Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While QUCY currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.26) and Max Pain ($0.88) forces dealer call-delta covering toward $5.18.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QUCYβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œQUCY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

QUCY Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (QUCY)

No recent open-market Form 4 cluster sales or emergency dumps flagged on QUCY. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QUCY)

  • βœ“Walkthrough of QUCY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
QUCY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +110.00%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-02O $0.84H $0.84L $0.80C $0.84VOL 110.9K
RES: $1.44SUP: $0.74SMA50: $1.26SMA200: $1.21
$5.25$3.91$2.57$1.23$-0.12RES $1.44SUP $0.74$0.842026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QUCY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QUCY today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for QUCY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QUCY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QUCY)

1. Head-to-Head Health Care Peer Comparison (QUCY vs. SDEV, INO, CRBP, RLYB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Quantum Cyber N.V. (QUCY) ranks #685 by composite RQD confidence (35/100, grade D-) and #688 by equity capitalization ($79.4M). Within this direct 5-issuer industry benchmark cohort, QUCY leads on earnings valuation at N/A trailing P/E, while QUCY leads on capital efficiency and profitability with -35.0% ROIC and 72.6% gross margin. CRBP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QUCY at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QUCY ACTIVE
Quantum Cyber N.V.
D- 35/100 β€” 72.6% -35.0% -7.69% $79.4M Benchmark Subject
SDEV
Stablecoin Development Corporation
D- 42/100 β€” β€” -35.0% -6.48% $79.0M /sdev-vs-qucy β†’
INO
Inovio Pharmaceuticals Inc.
E 34/100 β€” β€” -35.0% -21.95% $79.8M /ino-vs-qucy β†’
CRBP
Corbus Pharmaceuticals Holdings Inc.
D 47/100 β€” β€” -35.0% 0.00% $81.6M /crbp-vs-qucy β†’
RLYB
Rallybio Corporation
D- 37/100 β€” β€” -35.0% +0.84% $83.0M /rlyb-vs-qucy β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001874252

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quantum Cyber N.V. (QUCY) reported GAAP revenue of $537.1K (-39.9% vs. FY2024 revenue of $894.0K ) , GAAP net income of -$16.2M, operating cash flow of -$11.0M, and free cash flow of -$11.0M (+37.0% YoY). On the balance sheet, QUCY closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $537.1K -$16.2M -$11.0M -$11.0M $5.3M β€”
FY2024 (FY) 2024-12-31 $894.0K -$21.6M -$17.3M -$17.4M $13.5M β€”

3. QUCY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QUCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Quantum Cyber N.V. (NASDAQ: QUCY) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.84 (-7.69% 1D, market cap $79.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QUCY ranks #685 in composite RQD confidence.

How does QUCY compare to SDEV and INO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QUCY carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 72.6%, and ROIC of -35.0%. By comparison, SDEV (Stablecoin Development Corporation) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $79.0M) and INO (Inovio Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $79.8M). Among the 5-stock peer group, QUCY leads on earnings multiple (N/A) while QUCY leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QUCY?

Per QUCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001874252), Quantum Cyber N.V. generated $537.1K in revenue (-39.9% YoY), -$16.2M in net income, and -$11.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QUCY trading relative to its 50-day, 200-day, and 52-week technical levels?

QUCY last traded at $0.84 (-7.69% on volume of 360,846 shares), positioning the stock -33.33% below its 50-day simple moving average ($1.26) and -30.58% below its 200-day simple moving average ($1.21). Across its 52-week range of $0.30 to $4.93, QUCY sits at the 11.7% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $0.94).

QUCY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are QUCY insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies QUCY leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

QUCY β€” Quantum Cyber N.V.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:45:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, QUCY scores 35 out of 100, graded D- and labeled "Roarable Sell β€” Vulnerable Balance Sheet & Flow." The five pillars are:

  • Fundamental Cash Engine (8 / 20): Per the RQD rating, ROIC is -35% and FCF yield is -13.84%. For a prospective investor, this pillar signals that the business is not currently generating returns on capital or positive free cash flow, so any valuation rests on future cash generation that the source data does not demonstrate.
  • Whale 13F Flow (10 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The source data does not itemize the underlying 13F holdings, so the magnitude of this flow cannot be assessed beyond the score.
  • Insider Conviction (3 / 20): Per the RQD rating, this is the weakest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. A low score here means insider and disclosed-trade signals offer little confirmation of conviction in the stock.
  • Macro Regime Fit (6 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity. The stock is assessed as moving in line with the market, without a defensive or asymmetric macro profile.
  • Forensic Balance Sheet (8 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings point to a balance sheet that is neither clearly distressed nor robust, with weak internal financial-health indicators.

Taken together, the RQD framework frames QUCY as a speculative, cash-consuming issuer where the investment case depends on a turnaround in cash generation. Upside drivers would require evidence of narrowing losses and improving flow; valuation tradeoffs are severe given negative returns and cash burn; and the equity-financing catalyst noted below suggests ongoing dilution risk.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.5M$-16.1M$-16.2MN/A$-11.0MN/AN/A
FY 2024$0.9M$-18.8M$-21.6MN/A$-17.4MN/AN/A

Per the SEC financials, revenue declined from $0.9M in FY 2024 to $0.5M in FY 2025, while net loss narrowed from $-21.6M to $-16.2M. Per the market data, gross margin is 72.6%, while operating and net margins are both -60%. Per the Roarable RQD rating, ROIC is -35%, and the forensic balance sheet pillar reports an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. Cash and debt balances are not available in source data for either period.

Recent Catalysts & News Wire Analysis

  • $100 Million ATM Equity Program: Two headlines report the launch and filing of a $100 million at-the-market share offering, with one noting shares were down pre-bell. This is a dilution-relevant catalyst.
  • Senior Defense Talent / Strategic Program Coverage: A Benzinga headline ties QUCY and peers to senior defense talent recruitment amid a strategic program.
  • Quantum Antenna Technology Presentation: Stock Titan reports QUCY was invited to present quantum antenna technology at a quantum sensing convening.
  • Market Wire Coverage: Yahoo Finance UK, Barchart.com, and marketscreener.com items are general market-action coverage with no additional fundamental detail in the source data.

Risk watch items: dilution from the ATM program, negative operating momentum, and reliance on future technology milestones. Per the Butterfly Supply-Chain Graph, the supply-chain field is NONE and there are no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream or downstream dependencies, sector correlations, or second-order bottlenecks. An investor should note that the absence of mapped links means this analysis cannot identify ripple effects from the source data alone.

Open Questions

  • What are the company's specific products, clinical or commercial milestones, and customers? The profile gives only a sector label.
  • What are cash and debt balances for FY 2025 and FY 2024, and what is the runway at the current cash burn rate?
  • What are the terms, size utilization, and dilution impact of the $100 million ATM equity program?
  • Who are the institutional and insider holders, and what is the direction of their recent activity?
  • What drove the decline in revenue from $0.9M to $0.5M, and what is management's guidance?

QUCY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Quantum Cyber N.V. (QUCY) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to QUCY Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QUCY Bull vs. Bear Conversation Board β€” What's Your Call at $0.84?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QUCY 🐻 67% BEARISH CONVICTION
1. Pick Your Side on QUCY:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.80 (-12.1%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is QUCY (D- β€’ RQD 35/100) a Buy at $0.91?

Welcome to the QUCY (Quantum Cyber N.V.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.72 (-20.9%)
Spot @ $0.91

Pump the brakes on QUCY β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on QUCY, but look at what you are paying: current EV/EBITDA multiples with 72.6% gross margins. Unless Quantum Cyber N.V. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $1.04 (+14.3%)
Spot @ $0.91

QUCY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on QUCY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.91 (52-wk range $0.82 - $1.02), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%